Dr. Julie Paik completed her medical school training at the George Washington University School of Medicine in Washington, DC. She then completed her residency and chief residency at UCLA-Cedars-Sinai/VA Medical Center in Los Angeles, California. She completed rheumatology fellowship at Johns Hopkins and joined the faculty in 2013. She currently sees patients at the Johns Hopkins Myositis Center and Scleroderma Center. Her research interests are in myositis and scleroderma or overlap myositis. She also has a special interest in novel therapeutics in refractory dermatomyositis. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Paik is rated as an Elite provider by MediFind in the treatment of Polymyositis. Her top areas of expertise are Dermatomyositis, Polymyositis, Myositis, and Scleroderma.

Chester V. Oddis, MD is a noted researcher in the clinical, epidemiological and serologic description of the idiopathic inflammatory myopathies. He has completed epidemiological studies on the incidence of polymyositis and dermatomyositis as well as longitudinal studies on functional disability in myositis patients. His focus has been in the autoantibody patterns in patients with inflammatory myopathy and their peculiar immunogenetic associations.Dr. Oddis has written extensively on the diagnosis and management of patients with myositis. He has published and lectured on the use of novel immunosuppressive agents such as tacrolimus (formerly FK506) in the treatment of patients with refractory myositis. This represents the only reported experience of this particular drug in the pharmacologic treatment of inflammatory myopathy. In collaboration with the Department of Neurology, he has assessed the efficacy and utility of outpatient needle muscle biopsy in the diagnosis of inflammatory myopathy. This is important given the cost-containment focus of the current health-care market.Dr. Oddis is the co-investigator on an important national NIH funded study on the efficacy of doxycycline in preventing the progression of knee osteoarthritis in middle-aged women. This study is the first of its kind in assessing the effect of a disease-modifying agent in osteoarthritis.Board certified in internal medicine and rheumatology, Dr. Oddis received his medical degree from Pennsylvania State University, Milton S. Hershey Medical Center and his undergraduate degree from the University of Pittsburgh. He completed his residency in internal medicine at Penn State and fellowship at the University of Pittsburgh Medical Center. Dr. Oddis is rated as an Elite provider by MediFind in the treatment of Polymyositis. His top areas of expertise are Dermatomyositis, Myositis, Polymyositis, and Antisynthetase Syndrome.

Dr. Christopher-Stine is the Co-Founder and Director of the Johns Hopkins Myositis Center. She is a Professor of Medicine and Neurology. She is a longstanding core faculty member of the Johns Hopkins University School of Medicine College Advisory Program and serves as the Co-Chair of the Johns Hopkins Institutional Review Board (IRB 5). Dr. Christopher-Stine graduated Cum Laude with a B.A. in chemistry from Franklin and Marshall College; was elected to Alpha Omega Alpha at Hahnemann University School of Medicine, where she received her MD degree, and she attained her Masters of Public Health degree from the Johns Hopkins Bloomberg School of Public Health. Her internship and residency training were completed at MCP Hahnemann University, where she also served as Chief Resident. She pursued her rheumatology fellowship training at Johns Hopkins. Dr. Christopher is rated as an Elite provider by MediFind in the treatment of Polymyositis. Her top areas of expertise are Myositis, Polymyositis, Dermatomyositis, and Inclusion Body Myositis.